Yang L, Ma A. Cost-utilities Analysis of Polatuzumab Vedotin Combined with Bendamustine and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma Which Is Unsuited for Hematopoietic Stem Cell Transplantation. FBEM. 2023;8(3):178-184. doi:10.54097/fbem.v8i3.7835